Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 15, 2019 | Series B | $50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hartford HealthCare Endowment | — | Series B |